Considerations for Drug Interactions on QTc in Exploratory COVID-19 Treatment. Circulation. 2020 06 16; 141(24):e906-e907.

View in: PubMed

Score: 0.007

Initial Invasive or Conservative Strategy for Stable Coronary Disease. N Engl J Med. 2020 04 09; 382(15):1395-1407.

View in: PubMed

Score: 0.007

The Role of the American Heart Association in the Global COVID-19 Pandemic. Circulation. 2020 04 14; 141(15):e743-e745.

View in: PubMed

Score: 0.007

Sustained Low-Density Lipoprotein Cholesterol Lowering With Alirocumab in ODYSSEY?OUTCOMES. J Am Coll Cardiol. 2020 02 04; 75(4):448-451.

View in: PubMed

Score: 0.007

Advancing Healthcare Reform: The American Heart Association's 2020 Statement of Principles for Adequate, Accessible, and Affordable Health Care: A Presidential Advisory From the American Heart Association. Circulation. 2020 03 10; 141(10):e601-e614.

View in: PubMed

Score: 0.007

Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute?Coronary Syndrome. J Am Coll Cardiol. 2020 01 21; 75(2):133-144.

View in: PubMed

Score: 0.007

Association Between Current and Future Annual Hospital Percutaneous Coronary Intervention Mortality Rates. JAMA Cardiol. 2019 11 01; 4(11):1077-1083.

View in: PubMed

Score: 0.007

Guidelines for the Early Management of Patients With Acute Ischemic Stroke: 2019 Update to the 2018 Guidelines for the Early Management of Acute Ischemic Stroke. Stroke. 2019 12; 50(12):3331-3332.

View in: PubMed

Score: 0.007

Revisiting the Role of Aspirin for the Primary Prevention of Cardiovascular Disease. Circulation. 2019 09 24; 140(13):1115-1124.

View in: PubMed

Score: 0.007

Effects of Alirocumab on Cardiovascular Events After Coronary Bypass Surgery. J Am Coll Cardiol. 2019 09 03; 74(9):1177-1186.

View in: PubMed

Score: 0.006

Risk Categorization Using New American College of Cardiology/American Heart Association Guidelines for Cholesterol Management and Its Relation to Alirocumab Treatment Following Acute Coronary Syndromes. Circulation. 2019 11 05; 140(19):1578-1589.

View in: PubMed

Score: 0.006

Effects of alirocumab on types of myocardial infarction: insights from the ODYSSEY OUTCOMES trial. Eur Heart J. 2019 09 01; 40(33):2801-2809.

View in: PubMed

Score: 0.006

Ticagrelor in Patients with Stable Coronary Disease and Diabetes. N Engl J Med. 2019 Oct 03; 381(14):1309-1320.

View in: PubMed

Score: 0.006

Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial. Lancet. 2019 Sep 28; 394(10204):1169-1180.

View in: PubMed

Score: 0.006

Site Variation and Outcomes for Antithrombotic Therapy in Atrial Fibrillation Patients After Percutaneous Coronary Intervention. Circ Cardiovasc Interv. 2019 08; 12(8):e007604.

View in: PubMed

Score: 0.006

Central Adjudication Identified Additional and Prognostically Important Myocardial Infarctions in Patients Undergoing Percutaneous Coronary Intervention. Circ Cardiovasc Interv. 2019 07; 12(7):e007342.

View in: PubMed

Score: 0.006

Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial. Lancet Diabetes Endocrinol. 2019 08; 7(8):618-628.

View in: PubMed

Score: 0.006

Effect of Alirocumab on Mortality After Acute Coronary Syndromes. Circulation. 2019 07 09; 140(2):103-112.

View in: PubMed

Score: 0.006

Clinical consequences of bleeding among individuals with a recent acute coronary syndrome: Insights from the APPRAISE-2 trial. Am Heart J. 2019 09; 215:106-113.

View in: PubMed

Score: 0.006

Stanford Cardiovascular Institute. Circ Res. 2019 05 10; 124(10):1420-1424.

View in: PubMed

Score: 0.006

Comparison of Rates of Bleeding and Vascular Complications Before, During, and After Trial Enrollment in the SAFE-PCI Trial for Women. Circ Cardiovasc Interv. 2019 05; 12(5):e007086.

View in: PubMed

Score: 0.006

Rationale, design and baseline characteristics of the effect of ticagrelor on health outcomes in diabetes mellitus patients Intervention study. Clin Cardiol. 2019 May; 42(5):498-505.

View in: PubMed

Score: 0.006

Alirocumab in Patients With Polyvascular Disease and Recent Acute Coronary?Syndrome: ODYSSEY OUTCOMES Trial. J Am Coll Cardiol. 2019 09 03; 74(9):1167-1176.

View in: PubMed

Score: 0.006

Periprocedural Outcomes According to Timing of Clopidogrel Loading Dose in Patients Who Did Not Receive P2Y12 Inhibitor Pretreatment. Circ Cardiovasc Interv. 2019 03; 12(3):e007445.

View in: PubMed

Score: 0.006

Reduction of Cardiovascular Mortality and Ischemic Events in Acute Medically Ill Patients. Circulation. 2019 02 26; 139(9):1234-1236.

View in: PubMed

Score: 0.006

Association Between Female Corresponding Authors and Female Co-Authors in Top Contemporary Cardiovascular Medicine Journals. Circulation. 2019 02 19; 139(8):1127-1129.

View in: PubMed

Score: 0.006

Extended-duration betrixaban versus shorter-duration enoxaparin for venous thromboembolism prophylaxis in critically ill medical patients: an APEX trial substudy. Intensive Care Med. 2019 04; 45(4):477-487.

View in: PubMed

Score: 0.006

Sex Differences in the Pursuit of Interventional Cardiology as a Subspecialty Among Cardiovascular Fellows-in-Training. JACC Cardiovasc Interv. 2019 02 11; 12(3):219-228.

View in: PubMed

Score: 0.006

Stroke Outcomes With Vorapaxar Versus Placebo in Patients With Acute Coronary Syndromes: Insights From the TRACER Trial. J Am Heart Assoc. 2018 12 18; 7(24):e009609.

View in: PubMed

Score: 0.006

Impact of lesion complexity on peri-procedural adverse events and the benefit of potent intravenous platelet adenosine diphosphate receptor inhibition after percutaneous coronary intervention: core laboratory analysis from 10?854 patients from the CHAMPION PHOENIX trial. Eur Heart J. 2018 12 07; 39(46):4112-4121.

View in: PubMed

Score: 0.006

Characteristics and outcomes of patients requiring bailout use of glycoprotein IIb/IIIa inhibitors for thrombotic complications of percutaneous coronary intervention: An analysis from the CHAMPION PHOENIX trial. Int J Cardiol. 2019 Mar 01; 278:217-222.

View in: PubMed

Score: 0.006

Asymptomatic Deep Vein Thrombosis is Associated with an Increased Risk of Death: Insights from the APEX Trial. Thromb Haemost. 2018 Dec; 118(12):2046-2052.

View in: PubMed

Score: 0.006

Alirocumab Reduces Total Nonfatal Cardiovascular and Fatal Events: The ODYSSEY OUTCOMES Trial. J Am Coll Cardiol. 2019 02 05; 73(4):387-396.

View in: PubMed

Score: 0.006

Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome. N Engl J Med. 2018 11 29; 379(22):2097-2107.

View in: PubMed

Score: 0.006

Inverse relationship of serum albumin to the risk of venous thromboembolism among acutely ill hospitalized patients: Analysis from the APEX trial. Am J Hematol. 2019 01; 94(1):21-28.

View in: PubMed

Score: 0.006

Planning and Conducting the ISCHEMIA Trial. Circulation. 2018 10 02; 138(14):1384-1386.

View in: PubMed

Score: 0.006

Heart Centers for Women: Historical Perspective on Formation and Future Strategies to Reduce Cardiovascular Disease. Circulation. 2018 09 11; 138(11):1155-1165.

View in: PubMed

Score: 0.006

Effects of genetic variation in protease activated receptor 4 after an acute coronary syndrome: Analysis from the TRACER trial. Blood Cells Mol Dis. 2018 09; 72:37-43.

View in: PubMed

Score: 0.006

Using Digital Health Technology to?Better?Generate Evidence and Deliver?Evidence-Based?Care. J Am Coll Cardiol. 2018 06 12; 71(23):2680-2690.

View in: PubMed

Score: 0.006

Mobile Health Advances in Physical Activity, Fitness, and Atrial Fibrillation: Moving Hearts. J Am Coll Cardiol. 2018 06 12; 71(23):2691-2701.

View in: PubMed

Score: 0.006

Definitions of peri-procedural myocardial infarction and the association with one-year mortality: Insights from CHAMPION trials. Int J Cardiol. 2018 Nov 01; 270:96-101.

View in: PubMed

Score: 0.006

Prognostic and Practical Validation of Current Definitions of Myocardial Infarction Associated With Percutaneous?Coronary Intervention. JACC Cardiovasc Interv. 2018 05 14; 11(9):856-864.

View in: PubMed

Score: 0.006

Cost implications of intraprocedural thrombotic events and bleeding in percutaneous coronary intervention: Results from the CHAMPION PHOENIX ECONOMICS Study. Catheter Cardiovasc Interv. 2018 11 01; 92(5):E348-E355.

View in: PubMed

Score: 0.006

International Study of Comparative Health Effectiveness with Medical and Invasive Approaches (ISCHEMIA) trial: Rationale and design. Am Heart J. 2018 07; 201:124-135.

View in: PubMed

Score: 0.006

Discharge timing and outcomes after uncomplicated non-ST-segment elevation acute myocardial infarction. Am Heart J. 2018 07; 201:103-110.

View in: PubMed

Score: 0.006

Rediscovering the Orbit of Percutaneous Coronary Intervention After ORBITA. Circulation. 2018 06 05; 137(23):2427-2429.

View in: PubMed

Score: 0.006

Association of Anemia with Venous Thromboembolism in Acutely Ill Hospitalized Patients: An APEX Trial Substudy. Am J Med. 2018 08; 131(8):972.e1-972.e7.

View in: PubMed

Score: 0.006

Incidence, Predictors, and Outcomes of Acquired Thrombocytopenia After Percutaneous Coronary Intervention: A Pooled, Patient-Level Analysis of the CHAMPION Trials (Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition). Circ Cardiovasc Interv. 2018 04; 11(4):e005635.

View in: PubMed

Score: 0.006

Short- and long-term mortality following bleeding events in patients undergoing percutaneous coronary intervention: insights from four validated bleeding scales in the CHAMPION trials. EuroIntervention. 2018 02 02; 13(15):e1841-e1849.

View in: PubMed

Score: 0.006

Extended-Duration Betrixaban Reduces the Risk of Rehospitalization Associated With Venous Thromboembolism Among Acutely Ill Hospitalized Medical Patients: Findings From the APEX Trial (Acute Medically Ill Venous Thromboembolism Prevention With Extended Duration Betrixaban Trial). Circulation. 2018 01 02; 137(1):91-94.

View in: PubMed

Score: 0.006

Increased benefit of betrixaban among patients with a history of venous thromboembolism: a post-hoc analysis of the APEX trial. J Thromb Thrombolysis. 2018 Jan; 45(1):1-8.

View in: PubMed

Score: 0.006

Thrombus Burden of Deep Vein Thrombosis and Its Association with Thromboprophylaxis and D-Dimer Measurement: Insights from the APEX Trial. Thromb Haemost. 2017 12; 117(12):2389-2395.

View in: PubMed

Score: 0.006

N-terminal pro-B-type natriuretic peptide and the risk of stroke among patients hospitalized with acute heart failure: an APEX trial substudy. J Thromb Thrombolysis. 2017 Nov; 44(4):457-465.

View in: PubMed

Score: 0.006

Apixaban following acute coronary syndromes in patients with prior stroke: Insights from the APPRAISE-2 trial. Am Heart J. 2018 03; 197:1-8.

View in: PubMed

Score: 0.006

Clinical features and outcomes of patients with type 2 myocardial infarction: Insights from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) trial. Am Heart J. 2018 02; 196:28-35.

View in: PubMed

Score: 0.006

Cangrelor compared with clopidogrel in patients with prior myocardial infarction - Insights from the CHAMPION trials. Int J Cardiol. 2018 Jan 01; 250:49-55.

View in: PubMed

Score: 0.006

Competing risk analysis in a large cardiovascular clinical trial: An APEX substudy. Pharm Stat. 2017 11; 16(6):445-450.

View in: PubMed

Score: 0.006

Cangrelor in Older Patients Undergoing Percutaneous Coronary Intervention: Findings From CHAMPION PHOENIX. Circ Cardiovasc Interv. 2017 Aug; 10(8).

View in: PubMed

Score: 0.006

Cangrelor Versus Clopidogrel on a Background of Unfractionated Heparin (from CHAMPION PHOENIX). Am J Cardiol. 2017 Oct 01; 120(7):1043-1048.

View in: PubMed

Score: 0.006

Associations between tooth loss and prognostic biomarkers and the risk for cardiovascular events in patients with stable coronary heart disease. Int J Cardiol. 2017 Oct 15; 245:271-276.

View in: PubMed

Score: 0.006

Comparison of Fatal or Irreversible Events With Extended-Duration Betrixaban Versus Standard Dose Enoxaparin in Acutely Ill Medical Patients: An APEX Trial Substudy. J Am Heart Assoc. 2017 Jul 11; 6(7).

View in: PubMed

Score: 0.006

Use of Antiplatelet Therapy/DAPT for?Post-PCI Patients Undergoing Noncardiac Surgery. J Am Coll Cardiol. 2017 Apr 11; 69(14):1861-1870.

View in: PubMed

Score: 0.006

Obesity, Diabetes, and Acute Coronary Syndrome: Differences Between Asians and Whites. Am J Med. 2017 10; 130(10):1170-1176.

View in: PubMed

Score: 0.005

New Delivery Model for Rising-Risk Patients: The Forgotten Lot? Telemed J E Health. 2017 08; 23(8):649-653.

View in: PubMed

Score: 0.005

Potent P2Y12 Inhibitors in Men?Versus?Women: A?Collaborative?Meta-Analysis?of?Randomized?Trials. J Am Coll Cardiol. 2017 Mar 28; 69(12):1549-1559.

View in: PubMed

Score: 0.005

Levosimendan in Patients with Left Ventricular Dysfunction Undergoing Cardiac Surgery. N Engl J Med. 2017 05 25; 376(21):2032-2042.

View in: PubMed

Score: 0.005

The Academic Medical System: Reinvention to Survive the Revolution in Health Care. J Am Coll Cardiol. 2017 Mar 14; 69(10):1305-1312.

View in: PubMed

Score: 0.005

Trade-off of myocardial infarction vs. bleeding types on mortality after acute coronary syndrome: lessons from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) randomized trial. Eur Heart J. 2017 Mar 14; 38(11):804-810.

View in: PubMed

Score: 0.005

Cangrelor reduces the risk of ischemic complications in patients with single-vessel and multi-vessel disease undergoing percutaneous coronary intervention: Insights from the CHAMPION PHOENIX trial. Am Heart J. 2017 Jun; 188:147-155.

View in: PubMed

Score: 0.005

Disaggregation of Cause-Specific Cardiovascular Disease Mortality Among Hispanic Subgroups. JAMA Cardiol. 2017 03 01; 2(3):240-247.

View in: PubMed

Score: 0.005

Differential occurrence, profile, and impact of first recurrent cardiovascular events after an acute coronary syndrome. Am Heart J. 2017 May; 187:194-203.

View in: PubMed

Score: 0.005

Evaluation of Ischemic and Bleeding Risks Associated With 2 Parenteral Antiplatelet Strategies Comparing Cangrelor With Glycoprotein IIb/IIIa Inhibitors: An Exploratory Analysis From the CHAMPION Trials. JAMA Cardiol. 2017 02 01; 2(2):127-135.

View in: PubMed

Score: 0.005

Cangrelor With and Without Glycoprotein?IIb/IIIa Inhibitors in?Patients?Undergoing Percutaneous?Coronary Intervention. J Am Coll Cardiol. 2017 Jan 17; 69(2):176-185.

View in: PubMed

Score: 0.005

The Systematic Evaluation of Identifying the Infarct Related Artery Utilizing Cardiac Magnetic Resonance in Patients Presenting with ST-Elevation Myocardial Infarction. PLoS One. 2017; 12(1):e0169108.

View in: PubMed

Score: 0.005

Fasting glucose, NT-proBNP, treatment with eptifibatide, and outcomes in non-ST-segment elevation acute coronary syndromes: An analysis from EARLY ACS. Int J Cardiol. 2017 Apr 01; 232:264-270.

View in: PubMed

Score: 0.005

Feasibility of Obtaining Measures of Lifestyle From a Smartphone App: The MyHeart Counts Cardiovascular Health Study. JAMA Cardiol. 2017 01 01; 2(1):67-76.

View in: PubMed

Score: 0.005

Impact of Cerebrovascular Events Older Than One Year on Ischemic and Bleeding Outcomes With Cangrelor in Percutaneous Coronary Intervention. Circ Cardiovasc Interv. 2017 01; 10(1).

View in: PubMed

Score: 0.005

The safety and efficacy of full- versus reduced-dose betrixaban in the Acute Medically Ill VTE (Venous Thromboembolism) Prevention With Extended-Duration Betrixaban (APEX) trial. Am Heart J. 2017 Mar; 185:93-100.

View in: PubMed

Score: 0.005

Betrixaban in Acutely Ill Medical Patients. N Engl J Med. 2016 12 15; 375(24):e50.

View in: PubMed

Score: 0.005

Biomarkers and Coronary Lesions Predict Outcomes after Revascularization in Non-ST-Elevation Acute Coronary Syndrome. Clin Chem. 2017 Feb; 63(2):573-584.

View in: PubMed

Score: 0.005

Extended-Duration Betrixaban Reduces the Risk of Stroke Versus Standard-Dose Enoxaparin Among Hospitalized Medically Ill Patients: An APEX Trial Substudy (Acute Medically Ill Venous Thromboembolism Prevention With Extended Duration Betrixaban). Circulation. 2017 02 14; 135(7):648-655.

View in: PubMed

Score: 0.005

The Changing Landscape of Randomized Clinical Trials in Cardiovascular Disease. J Am Coll Cardiol. 2016 10 25; 68(17):1898-1907.

View in: PubMed

Score: 0.005

Efficacy and Safety of Cangrelor in Preventing Periprocedural Complications in Patients With Stable Angina and Acute?Coronary Syndromes Undergoing Percutaneous Coronary Intervention: The CHAMPION PHOENIX Trial. JACC Cardiovasc Interv. 2016 09 26; 9(18):1905-13.

View in: PubMed

Score: 0.005

Use of thienopyridine prior to presentation with non-ST-segment elevation acute coronary syndrome and association with safety and efficacy of vorapaxar: insights from the TRACER trial. Eur Heart J Acute Cardiovasc Care. 2017 Mar; 6(2):155-163.

View in: PubMed

Score: 0.005

Levosimendan in patients with left ventricular systolic dysfunction undergoing cardiac surgery on cardiopulmonary bypass: Rationale and study design of the Levosimendan in Patients with Left Ventricular Systolic Dysfunction Undergoing Cardiac Surgery Requiring Cardiopulmonary Bypass (LEVO-CTS) trial. Am Heart J. 2016 Dec; 182:62-71.

View in: PubMed

Score: 0.005

"Off-Hours" Versus "On-Hours" Presentation in ST-Segment Elevation Myocardial Infarction: CHAMPION PHOENIX Findings. J Am Coll Cardiol. 2016 11 29; 68(21):2385-2387.

View in: PubMed

Score: 0.005

Sharing Data from Cardiovascular Clinical Trials--A Proposal. N Engl J Med. 2016 Aug 04; 375(5):407-9.

View in: PubMed

Score: 0.005

Implications of different criteria for percutaneous coronary intervention-related myocardial infarction on study results of three large phase III clinical trials: The CHAMPION experience. Eur Heart J Acute Cardiovasc Care. 2018 Mar; 7(2):158-165.

View in: PubMed

Score: 0.005

Consistent Reduction in Periprocedural Myocardial Infarction With Cangrelor as Assessed by Multiple Definitions: Findings From CHAMPION PHOENIX (Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition). Circulation. 2016 Sep 06; 134(10):723-33.

View in: PubMed

Score: 0.005

Radial access in patients with acute coronary syndrome without persistent ST-segment elevation: Systematic review, collaborative meta-analysis, and meta-regression. Int J Cardiol. 2016 Nov 01; 222:1031-1039.

View in: PubMed

Score: 0.005

Defining a Mobile Health Roadmap for Cardiovascular Health and Disease. J Am Heart Assoc. 2016 07 12; 5(7).

View in: PubMed

Score: 0.005

Lipoprotein-Associated Phospholipase A2 Activity Is a Marker of Risk But Not a Useful Target for Treatment in Patients With Stable Coronary Heart Disease. J Am Heart Assoc. 2016 06 21; 5(6).

View in: PubMed

Score: 0.005

Effect of age on efficacy and safety of vorapaxar in patients with non-ST-segment elevation acute coronary syndrome: Insights from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) trial. Am Heart J. 2016 08; 178:176-84.

View in: PubMed

Score: 0.005

Variation in Patient Profiles and Outcomes in US and Non-US Subgroups of the Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition (CHAMPION) PHOENIX Trial. Circ Cardiovasc Interv. 2016 06; 9(6).

View in: PubMed

Score: 0.005

Extended Thromboprophylaxis with Betrixaban in Acutely Ill Medical Patients. N Engl J Med. 2016 08 11; 375(6):534-44.

View in: PubMed

Score: 0.005

Response to Letters Regarding Article, "Frequency and Predictors of Internal Mammary Artery Graft Failure and Subsequent Clinical Outcomes: Insights From the Project of Ex-Vivo Vein Graft Engineering via Transfection (PREVENT) IV Trial". Circulation. 2016 May 24; 133(21):e665.

View in: PubMed

Score: 0.005

Validation of BARC Bleeding Criteria in Patients With Acute Coronary Syndromes: The TRACER Trial. J Am Coll Cardiol. 2016 May 10; 67(18):2135-2144.

View in: PubMed

Score: 0.005

Autologous CD34+ Cell Therapy for Refractory Angina: 2-Year Outcomes From the ACT34-CMI Study. Cell Transplant. 2016; 25(9):1701-1711.

View in: PubMed

Score: 0.005

Lack of Concordance Between Local Investigators, Angiographic Core Laboratory, and Clinical Event Committee in the Assessment of Stent Thrombosis: Results From the TRACER Angiographic Substudy. Circ Cardiovasc Interv. 2016 May; 9(5):e003114.

View in: PubMed

Score: 0.005

Albuminuria and cardiovascular events in patients with acute coronary syndromes: Results from the TRACER trial. Am Heart J. 2016 Aug; 178:1-8.

View in: PubMed

Score: 0.005

Impact of glycoprotein IIb/IIIa inhibitors on the efficacy and safety of ticagrelor compared with clopidogrel in patients with acute coronary syndromes: Analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial. Am Heart J. 2016 Jul; 177:1-8.

View in: PubMed

Score: 0.005

Sudden Cardiac Death After Non-ST-Segment Elevation Acute Coronary Syndrome. JAMA Cardiol. 2016 04 01; 1(1):73-9.

View in: PubMed

Score: 0.005

Trends in Enrollment, Clinical Characteristics, Treatment, and Outcomes According to Age in Non-ST-Segment-Elevation Acute Coronary Syndromes Clinical Trials. Circulation. 2016 Apr 19; 133(16):1560-73.

View in: PubMed

Score: 0.005

Investigator-Reported Bleeding Versus Post Hoc Adjudication of Bleeding: Lessons From the CHAMPION PHOENIX Trial. J Am Coll Cardiol. 2016 Feb 09; 67(5):596-8.

View in: PubMed

Score: 0.005

Safety and efficacy of ticagrelor and clopidogrel in primary percutaneous coronary intervention. Heart. 2016 Apr; 102(8):617-25.

View in: PubMed

Score: 0.005

Efficacy and Safety of Cangrelor in Women Versus Men During Percutaneous Coronary Intervention: Insights From the Cangrelor versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition (CHAMPION PHOENIX) Trial. Circulation. 2016 Jan 19; 133(3):248-55.

View in: PubMed

Score: 0.005

Arterial access site and outcomes in patients undergoing percutaneous coronary intervention with and without vorapaxar. Catheter Cardiovasc Interv. 2016 Aug; 88(2):163-73.

View in: PubMed

Score: 0.005

Tooth loss is independently associated with poor outcomes in stable coronary heart disease. Eur J Prev Cardiol. 2016 05; 23(8):839-46.

View in: PubMed

Score: 0.005

Efficacy and Safety of Vorapaxar in Non-ST-Segment Elevation Acute Coronary Syndrome Patients Undergoing Noncardiac Surgery. J Am Heart Assoc. 2015 Dec 15; 4(12).

View in: PubMed

Score: 0.005

Frequency and Predictors of Internal Mammary Artery Graft Failure and Subsequent Clinical Outcomes: Insights From the Project of Ex-vivo Vein Graft Engineering via Transfection (PREVENT) IV Trial. Circulation. 2016 Jan 12; 133(2):131-8.

View in: PubMed

Score: 0.005

Medical Therapy With Versus Without Revascularization in Stable Patients With Moderate and Severe Ischemia: The Case for Community Equipoise. J Am Coll Cardiol. 2016 Jan 05; 67(1):81-99.

View in: PubMed

Score: 0.005

Frequency, clinical and angiographic characteristics, and outcomes of high-risk non-ST-segment elevation acute coronary syndromes patients with left circumflex culprit lesions. Int J Cardiol. 2016 Jan 15; 203:708-13.

View in: PubMed

Score: 0.005

Acquisition, Analysis, and Sharing of Data in 2015 and Beyond: A Survey of the Landscape: A Conference Report From the American Heart Association Data Summit 2015. J Am Heart Assoc. 2015 Nov 05; 4(11).

View in: PubMed

Score: 0.005

Association of spontaneous and procedure-related bleeds with short- and long-term mortality after acute coronary syndromes: an analysis from the PLATO trial. EuroIntervention. 2015 Nov; 11(7):737-45.

View in: PubMed

Score: 0.005

Clinician Innovator: A Novel Career Path in Academic Medicine A Presidentially Commissioned Article From the American Heart Association. J Am Heart Assoc. 2015 Oct 08; 4(10):e001990.

View in: PubMed

Score: 0.005

The effect of cangrelor and access site on ischaemic and bleeding events: insights from CHAMPION PHOENIX. Eur Heart J. 2016 Apr 07; 37(14):1122-30.

View in: PubMed

Score: 0.005

High-degree atrioventricular block, asystole, and electro-mechanical dissociation complicating non-ST-segment elevation myocardial infarction. Am Heart J. 2016 Jan; 171(1):25-32.

View in: PubMed

Score: 0.005

Extended-Duration Thromboprophylaxis Among Acute Medically Ill Patients: An Unmet Need. J Cardiovasc Pharmacol Ther. 2016 05; 21(3):227-32.

View in: PubMed

Score: 0.005

Sex-Stratified Trends in Enrollment, Patient Characteristics, Treatment, and Outcomes Among Non-ST-Segment Elevation Acute Coronary Syndrome Patients: Insights From Clinical Trials Over 17 Years. Circ Cardiovasc Qual Outcomes. 2015 Jul; 8(4):357-67.

View in: PubMed

Score: 0.005

Characterising and predicting bleeding in high-risk patients with an acute coronary syndrome. Heart. 2015 Sep; 101(18):1475-84.

View in: PubMed

Score: 0.005

Meta-analysis of intracranial hemorrhage in acute coronary syndromes: incidence, predictors, and clinical outcomes. J Am Heart Assoc. 2015 Jun 18; 4(6):e001512.

View in: PubMed

Score: 0.005

Magnitude of troponin elevation and long-term clinical outcomes in acute coronary syndrome patients treated with and without revascularization. Circ Cardiovasc Interv. 2015 Jun; 8(6):e002314.

View in: PubMed

Score: 0.005

Comparison of quality-of-life measures after radial versus femoral artery access for cardiac catheterization in women: Results of the Study of Access Site for Enhancement of Percutaneous Coronary Intervention for Women quality-of-life substudy. Am Heart J. 2015 Aug; 170(2):371-9.

View in: PubMed

Score: 0.005

The future of cardiovascular clinical research in North America and beyond-addressing challenges and leveraging opportunities through unique academic and grassroots collaborations. Am Heart J. 2015 Jun; 169(6):743-50.

View in: PubMed

Score: 0.005

Economic analysis of ticagrelor therapy from a U.S. perspective: results from the PLATO study. J Am Coll Cardiol. 2015 Feb 10; 65(5):465-76.

View in: PubMed

Score: 0.005

Anticoagulant therapy and outcomes in patients with prior or acute heart failure and acute coronary syndromes: Insights from the APixaban for PRevention of Acute ISchemic Events 2 trial. Am Heart J. 2015 Apr; 169(4):531-8.

View in: PubMed

Score: 0.005

Extent, location, and clinical significance of non-infarct-related coronary artery disease among patients with ST-elevation myocardial infarction. JAMA. 2014 Nov 19; 312(19):2019-27.

View in: PubMed

Score: 0.005

Vorapaxar with or without clopidogrel after non-ST-segment elevation acute coronary syndromes: results from the thrombin receptor antagonist for clinical event reduction in acute coronary syndrome trial. Am Heart J. 2014 Dec; 168(6):869-77.e1.

View in: PubMed

Score: 0.005

Predictors of contemporary coronary artery bypass grafting outcomes. J Thorac Cardiovasc Surg. 2014 Dec; 148(6):2720-6.e1-2.

View in: PubMed

Score: 0.005

Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial. Am Heart J. 2014 Nov; 168(5):682-9.

View in: PubMed

Score: 0.005

Vein graft preservation solutions, patency, and outcomes after coronary artery bypass graft surgery: follow-up from the PREVENT IV randomized clinical trial. JAMA Surg. 2014 Aug; 149(8):798-805.

View in: PubMed

Score: 0.005

A registry-based randomized trial comparing radial and femoral approaches in women undergoing percutaneous coronary intervention: the SAFE-PCI for Women (Study of Access Site for Enhancement of PCI for Women) trial. JACC Cardiovasc Interv. 2014 Aug; 7(8):857-67.

View in: PubMed

Score: 0.005

Vorapaxar in patients with peripheral artery disease and acute coronary syndrome: insights from Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER). Am Heart J. 2014 Oct; 168(4):588-96.

View in: PubMed

Score: 0.005

A 'green button' for using aggregate patient data at the point of care. Health Aff (Millwood). 2014 Jul; 33(7):1229-35.

View in: PubMed

Score: 0.005

No misrepresentation of vital status follow-up in PLATO: predefined analyses guarantee the integrity of the benefits of ticagrelor over clopidogrel in the PLATO trial: Commentary on: DiNicolantonio JJ, Tomek A, Misrepresentation of vital status follow-up: challenging the integrity of the PLATO trial and the claimed mortality benefit of ticagrelor versus clopidogrel, International Journal of Cardiology, 2013 Serebruany VL. Discrepancies in the primary PLATO trial publication and the FDA reviews, International Journal of Cardiology, 2014. Int J Cardiol. 2014 Sep; 176(1):300-2.

View in: PubMed

Score: 0.005

Usefulness and safety of vorapaxar in patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention (from the TRACER Trial). Am J Cardiol. 2014 Sep 01; 114(5):665-73.

View in: PubMed

Score: 0.005

Response to letter regarding article, "Stent thrombosis with ticagrelor versus clopidogrel in patients with acute coronary syndromes: an analysis from the prospective, randomized PLATO trial". Circulation. 2014 May 13; 129(19):e494-5.

View in: PubMed

Score: 0.004

Association of metabolic syndrome and its individual components with outcomes among patients with high-risk non-ST-segment elevation acute coronary syndromes. Am Heart J. 2014 Aug; 168(2):182-8.e1.

View in: PubMed

Score: 0.004

From abstract to peer-reviewed publication: country matters. Int J Cardiol. 2014 Jul 01; 174(3):830-2.

View in: PubMed

Score: 0.004

Ticagrelor vs. clopidogrel in patients with non-ST-elevation acute coronary syndrome with or without revascularization: results from the PLATO trial. Eur Heart J. 2014 Aug 14; 35(31):2083-93.

View in: PubMed

Score: 0.004

Darapladib for preventing ischemic events in stable coronary heart disease. N Engl J Med. 2014 May 01; 370(18):1702-11.

View in: PubMed

Score: 0.004

Vorapaxar, a platelet thrombin-receptor antagonist, in medically managed patients with non-ST-segment elevation acute coronary syndrome: results from the TRACER trial. Eur Heart J Acute Cardiovasc Care. 2014 Sep; 3(3):246-56.

View in: PubMed

Score: 0.004

Ticagrelor effects on myocardial infarction and the impact of event adjudication in the PLATO (Platelet Inhibition and Patient Outcomes) trial. J Am Coll Cardiol. 2014 Apr 22; 63(15):1493-9.

View in: PubMed

Score: 0.004

Vorapaxar in acute coronary syndrome patients undergoing coronary artery bypass graft surgery: subgroup analysis from the TRACER trial (Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome). J Am Coll Cardiol. 2014 Mar 25; 63(11):1048-57.

View in: PubMed

Score: 0.004

Relationship between postoperative clopidogrel use and subsequent angiographic and clinical outcomes following coronary artery bypass grafting. J Thromb Thrombolysis. 2013 Nov; 36(4):384-93.

View in: PubMed

Score: 0.004

EPC mobilization after erythropoietin treatment in acute ST-elevation myocardial infarction: the REVEAL EPC substudy. J Thromb Thrombolysis. 2013 Nov; 36(4):375-83.

View in: PubMed

Score: 0.004

Impact of intraprocedural stent thrombosis during percutaneous coronary intervention: insights from the CHAMPION PHOENIX Trial (Clinical Trial Comparing Cangrelor to Clopidogrel Standard of Care Therapy in Subjects Who Require Percutaneous Coronary Intervention). J Am Coll Cardiol. 2014 Feb 25; 63(7):619-629.

View in: PubMed

Score: 0.004

Biomarkers in relation to the effects of ticagrelor in comparison with clopidogrel in non-ST-elevation acute coronary syndrome patients managed with or without in-hospital revascularization: a substudy from the Prospective Randomized Platelet Inhibition and Patient Outcomes (PLATO) trial. Circulation. 2014 Jan 21; 129(3):293-303.

View in: PubMed

Score: 0.004

Effect of levosimendan on survival and adverse events after cardiac surgery: a meta-analysis. J Cardiothorac Vasc Anesth. 2013 Dec; 27(6):1224-32.

View in: PubMed

Score: 0.004

Association between bleeding and mortality among women and men with high-risk acute coronary syndromes: insights from the Early versus Delayed, Provisional Eptifibatide in Acute Coronary Syndromes (EARLY ACS) trial. Am Heart J. 2013 Oct; 166(4):723-8.

View in: PubMed

Score: 0.004

Effect of cangrelor on periprocedural outcomes in percutaneous coronary interventions: a pooled analysis of patient-level data. Lancet. 2013 Dec 14; 382(9909):1981-92.

View in: PubMed

Score: 0.004

Ferric carboxymaltose in patients with iron-deficiency anemia and impaired renal function: the REPAIR-IDA trial. Nephrol Dial Transplant. 2014 Apr; 29(4):833-42.

View in: PubMed

Score: 0.004

Stent thrombosis with ticagrelor versus clopidogrel in patients with acute coronary syndromes: an analysis from the prospective, randomized PLATO trial. Circulation. 2013 Sep 03; 128(10):1055-65.

View in: PubMed

Score: 0.004

Platelet inhibition with cangrelor during PCI. N Engl J Med. 2013 07 25; 369(4):393-4.

View in: PubMed

Score: 0.004

Routine early eptifibatide versus delayed provisional use at percutaneous coronary intervention in high-risk non-ST-segment elevation acute coronary syndromes patients: an analysis from the Early Glycoprotein IIb/IIIa Inhibition in Non-ST-Segment Elevation Acute Coronary Syndrome trial. Am Heart J. 2013 Sep; 166(3):466-73.

View in: PubMed

Score: 0.004

Response to letters regarding article, ?Conversion of cardiovascular conference abstracts to publications?. Circulation. 2013 Jul 09; 128(2):e29.

View in: PubMed

Score: 0.004

Angiographic outcomes in the PLATO Trial (Platelet Inhibition and Patient Outcomes). JACC Cardiovasc Interv. 2013 Jul; 6(7):671-83.

View in: PubMed

Score: 0.004

Response to letter regarding article, "Ticagrelor in patients with acute coronary syndromes and stroke: interpretation of subgroups in clinical trials". Stroke. 2013 Aug; 44(8):e95-6.

View in: PubMed

Score: 0.004

Quantitative ST-depression in acute coronary syndromes: the PLATO electrocardiographic substudy. Am J Med. 2013 Aug; 126(8):723-729.e1.

View in: PubMed

Score: 0.004

A multicenter, randomized, active-controlled study to investigate the efficacy and safety of intravenous ferric carboxymaltose in patients with iron deficiency anemia. Transfusion. 2014 Feb; 54(2):306-15.

View in: PubMed

Score: 0.004

Heart failure complicating non-ST-segment elevation acute coronary syndrome: timing, predictors, and clinical outcomes. JACC Heart Fail. 2013 Jun; 1(3):223-9.

View in: PubMed

Score: 0.004

2013 ACCF/AHA key data elements and definitions for measuring the clinical management and outcomes of patients with acute coronary syndromes and coronary artery disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Acute Coronary Syndromes and Coronary Artery Disease Clinical Data Standards). Crit Pathw Cardiol. 2013 Jun; 12(2):65-105.

View in: PubMed

Score: 0.004

Response to letter regarding article, ?sustained ventricular tachycardia and ventricular fibrillation complicating non?ST-segment elevation acute coronary syndromes?. Circulation. 2013 May 21; 127(20):e634.

View in: PubMed

Score: 0.004

Cardiac troponin after percutaneous coronary intervention and 1-year mortality in non-ST-segment elevation acute coronary syndrome using systematic evaluation of biomarker trends. J Am Coll Cardiol. 2013 Jul 16; 62(3):242-251.

View in: PubMed

Score: 0.004

Outcomes among non-ST-segment elevation acute coronary syndromes patients with no angiographically obstructive coronary artery disease: observations from 37,101 patients. Eur Heart J Acute Cardiovasc Care. 2014 Mar; 3(1):37-45.

View in: PubMed

Score: 0.004

A phase 3, randomized, double-blinded, active-controlled, unblinded standard of care study assessing the efficacy and safety of intramyocardial autologous CD34+ cell administration in patients with refractory angina: design of the RENEW study. Am Heart J. 2013 Jun; 165(6):854-861.e2.

View in: PubMed

Score: 0.004

Ticagrelor in patients with acute coronary syndromes and stroke: interpretation of subgroups in clinical trials. Stroke. 2013 May; 44(5):1477-9.

View in: PubMed

Score: 0.004

Left bundle branch block in non-ST-segment elevation acute coronary syndromes. Incidence, angiographic characteristics, and clinical outcomes. J Am Coll Cardiol. 2013 Apr 02; 61(13):1461-3.

View in: PubMed

Score: 0.004

Effect of vorapaxar on myocardial infarction in the thrombin receptor antagonist for clinical event reduction in acute coronary syndrome (TRA?CER) trial. Eur Heart J. 2013 Jun; 34(23):1723-31.

View in: PubMed

Score: 0.004

Rescuing clinical trials in the United States and beyond: a call for action. Am Heart J. 2013 Jun; 165(6):837-47.

View in: PubMed

Score: 0.004

Effect of platelet inhibition with cangrelor during PCI on ischemic events. N Engl J Med. 2013 Apr 04; 368(14):1303-13.

View in: PubMed

Score: 0.004

A novel approach to systematically implement the universal definition of myocardial infarction: insights from the CHAMPION PLATFORM trial. Heart. 2013 Sep; 99(17):1282-7.

View in: PubMed

Score: 0.004

Radial versus femoral access, bleeding and ischemic events in patients with non-ST-segment elevation acute coronary syndrome managed with an invasive strategy. Am Heart J. 2013 Apr; 165(4):583-590.e1.

View in: PubMed

Score: 0.004

Prevalence and clinical outcomes of undiagnosed diabetes mellitus and prediabetes among patients with high-risk non-ST-segment elevation acute coronary syndrome. Am Heart J. 2013 Jun; 165(6):918-925.e2.

View in: PubMed

Score: 0.004

2013 ACCF/AHA key data elements and definitions for measuring the clinical management and outcomes of patients with acute coronary syndromes and coronary artery disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Acute Coronary Syndromes and Coronary Artery Disease Clinical Data Standards). Circulation. 2013 Mar 05; 127(9):1052-89.

View in: PubMed

Score: 0.004

2013 ACCF/AHA key data elements and definitions for measuring the clinical management and outcomes of patients with acute coronary syndromes and coronary artery disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on clinical data standards (writing committee to develop acute coronary syndromes and coronary artery disease clinical data standards). J Am Coll Cardiol. 2013 Mar 05; 61(9):992-1025.

View in: PubMed

Score: 0.004

Conversion of cardiovascular conference abstracts to publications. Circulation. 2012 Dec 11; 126(24):2819-25.

View in: PubMed

Score: 0.004

Incidence and clinical significance of cardiac biomarker elevation during stem cell mobilization, apheresis, and intramyocardial delivery: an analysis from ACT34-CMI. Am Heart J. 2012 Nov; 164(5):689-697.e3.

View in: PubMed

Score: 0.004

2012 ACCF/AATS/SCAI/STS expert consensus document on transcatheter aortic valve replacement: developed in collabration with the American Heart Association, American Society of Echocardiography, European Association for Cardio-Thoracic Surgery, Heart Failure Society of America, Mended Hearts, Society of Cardiovascular Anesthesiologists, Society of Cardiovascular Computed Tomography, and Society for Cardiovascular Magnetic Resonance. J Thorac Cardiovasc Surg. 2012 Sep; 144(3):e29-84.

View in: PubMed

Score: 0.004

Edifoligide and long-term outcomes after coronary artery bypass grafting: PRoject of Ex-vivo Vein graft ENgineering via Transfection IV (PREVENT IV) 5-year results. Am Heart J. 2012 Sep; 164(3):379-386.e1.

View in: PubMed

Score: 0.004

Association between angiographic complications and clinical outcomes among patients with acute coronary syndrome undergoing percutaneous coronary intervention: an EARLY ACS (Early Glycoprotein IIb/IIIa Inhibition in Non-ST-Segment Elevation Acute Coronary Syndrome) angiographic substudy. JACC Cardiovasc Interv. 2012 Sep; 5(9):927-35.

View in: PubMed

Score: 0.004

Age, treatment, and outcomes in high-risk non-ST-segment elevation acute coronary syndrome patients: insights from the EARLY ACS trial. Int J Cardiol. 2013 Sep 10; 167(6):2580-7.

View in: PubMed

Score: 0.004

Effect of adenosine-regulating agent acadesine on morbidity and mortality associated with coronary artery bypass grafting: the RED-CABG randomized controlled trial. JAMA. 2012 Jul 11; 308(2):157-64.

View in: PubMed

Score: 0.004

Highlights from the IV International Symposium of Thrombosis and Anticoagulation (ISTA), October 20-21, 2011, Salvador, Bahia, Brazil. J Thromb Thrombolysis. 2012 Jul; 34(1):143-63.

View in: PubMed

Score: 0.004

Sustained ventricular tachycardia and ventricular fibrillation complicating non-ST-segment-elevation acute coronary syndromes. Circulation. 2012 Jul 03; 126(1):41-9.

View in: PubMed

Score: 0.004

A randomized, double-blind, active-controlled phase 2 trial to evaluate a novel selective and reversible intravenous and oral P2Y12 inhibitor elinogrel versus clopidogrel in patients undergoing nonurgent percutaneous coronary intervention: the INNOVATE-PCI trial. Circ Cardiovasc Interv. 2012 Jun; 5(3):336-46.

View in: PubMed

Score: 0.004

Pharmacokinetic and pharmacodynamic effects of elinogrel: results of the platelet function substudy from the intravenous and oral administration of elinogrel to evaluate tolerability and efficacy in nonurgent percutaneous coronary intervention patients (INNOVATE-PCI) trial. Circ Cardiovasc Interv. 2012 Jun; 5(3):347-56.

View in: PubMed

Score: 0.004

Rationale and design of the Cangrelor versus standard therapy to acHieve optimal Management of Platelet InhibitiON PHOENIX trial. Am Heart J. 2012 May; 163(5):768-776.e2.

View in: PubMed

Score: 0.004

2012 ACCF/AATS/SCAI/STS expert consensus document on transcatheter aortic valve replacement: developed in collaboration with the American Heart Association, American Society of Echocardiography, European Association for Cardio-Thoracic Surgery, Heart Failure Society of America, Mended Hearts, Society of Cardiovascular Anesthesiologists, Society of Cardiovascular Computed Tomography, and Society for Cardiovascular Magnetic Resonance. Catheter Cardiovasc Interv. 2012 Jun 01; 79(7):1023-82.

View in: PubMed

Score: 0.004

Regional patterns of use of a medical management strategy for patients with non-ST-segment elevation acute coronary syndromes: insights from the EARLY ACS Trial. Circ Cardiovasc Qual Outcomes. 2012 Mar 01; 5(2):205-13.

View in: PubMed

Score: 0.004

Reduced immediate ischemic events with cangrelor in PCI: a pooled analysis of the CHAMPION trials using the universal definition of myocardial infarction. Am Heart J. 2012 Feb; 163(2):182-90.e4.

View in: PubMed

Score: 0.004

Association of proton pump inhibitor use on cardiovascular outcomes with clopidogrel and ticagrelor: insights from the platelet inhibition and patient outcomes trial. Circulation. 2012 Feb 28; 125(8):978-86.

View in: PubMed

Score: 0.004

Relationship between vein graft failure and subsequent clinical outcomes after coronary artery bypass surgery. Circulation. 2012 Feb 14; 125(6):749-56.

View in: PubMed

Score: 0.004

ST-elevation acute coronary syndromes in the Platelet Inhibition and Patient Outcomes (PLATO) trial: insights from the ECG substudy. Circulation. 2012 Jan 24; 125(3):514-21.

View in: PubMed

Score: 0.004

Bleeding complications with the P2Y12 receptor antagonists clopidogrel and ticagrelor in the PLATelet inhibition and patient Outcomes (PLATO) trial. Eur Heart J. 2011 Dec; 32(23):2933-44.

View in: PubMed

Score: 0.004

Thrombin-receptor antagonist vorapaxar in acute coronary syndromes. N Engl J Med. 2012 Jan 05; 366(1):20-33.

View in: PubMed

Score: 0.004

Safety and efficacy of adjusted-dose eptifibatide in patients with acute coronary syndromes and reduced renal function. Am Heart J. 2011 Nov; 162(5):884-892.e1.

View in: PubMed

Score: 0.004

Pulmonary function in patients with acute coronary syndrome treated with ticagrelor or clopidogrel (from the Platelet Inhibition and Patient Outcomes [PLATO] pulmonary function substudy). Am J Cardiol. 2011 Dec 01; 108(11):1542-6.

View in: PubMed

Score: 0.004

Highlights from the III International Symposium of Thrombosis and Anticoagulation (ISTA), October 14-16, 2010, S?o Paulo, Brazil. J Thromb Thrombolysis. 2011 Aug; 32(2):242-66.

View in: PubMed

Score: 0.004

Characterization of dyspnoea in PLATO study patients treated with ticagrelor or clopidogrel and its association with clinical outcomes. Eur Heart J. 2011 Dec; 32(23):2945-53.

View in: PubMed

Score: 0.004

Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med. 2011 Aug 25; 365(8):699-708.

View in: PubMed

Score: 0.004

Intramyocardial, autologous CD34+ cell therapy for refractory angina. Circ Res. 2011 Aug 05; 109(4):428-36.

View in: PubMed

Score: 0.004

ACCF/AHA 2011 expert consensus document on hypertension in the elderly: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents developed in collaboration with the American Academy of Neurology, American Geriatrics Society, American Society for Preventive Cardiology, American Society of Hypertension, American Society of Nephrology, Association of Black Cardiologists, and European Society of Hypertension. J Am Soc Hypertens. 2011 Jul-Aug; 5(4):259-352.

View in: PubMed

Score: 0.004

Saphenous vein grafts with multiple versus single distal targets in patients undergoing coronary artery bypass surgery: one-year graft failure and five-year outcomes from the Project of Ex-Vivo Vein Graft Engineering via Transfection (PREVENT) IV trial. Circulation. 2011 Jul 19; 124(3):280-8.

View in: PubMed

Score: 0.004

Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial. Circulation. 2011 Aug 02; 124(5):544-54.

View in: PubMed

Score: 0.004

Ticagrelor versus clopidogrel in patients with acute coronary syndromes intended for non-invasive management: substudy from prospective randomised PLATelet inhibition and patient Outcomes (PLATO) trial. BMJ. 2011 Jun 17; 342:d3527.

View in: PubMed

Score: 0.004

The incidence of bradyarrhythmias and clinical bradyarrhythmic events in patients with acute coronary syndromes treated with ticagrelor or clopidogrel in the PLATO (Platelet Inhibition and Patient Outcomes) trial: results of the continuous electrocardiographic assessment substudy. J Am Coll Cardiol. 2011 May 10; 57(19):1908-16.

View in: PubMed

Score: 0.004

ACCF/AHA 2011 expert consensus document on hypertension in the elderly: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. Circulation. 2011 May 31; 123(21):2434-506.

View in: PubMed

Score: 0.004

Upstream clopidogrel use and the efficacy and safety of early eptifibatide treatment in patients with acute coronary syndrome: an analysis from the Early Glycoprotein IIb/IIIa Inhibition in Patients with Non-ST-Segment Elevation Acute Coronary Syndrome (EARLY ACS) trial. Circulation. 2011 Feb 22; 123(7):722-30.

View in: PubMed

Score: 0.004

Ticagrelor versus clopidogrel in patients with acute coronary syndromes undergoing coronary artery bypass surgery: results from the PLATO (Platelet Inhibition and Patient Outcomes) trial. J Am Coll Cardiol. 2011 Feb 08; 57(6):672-84.

View in: PubMed

Score: 0.004

Patterns of discharge antiplatelet therapy and late outcomes among 8,582 patients with bleeding during acute coronary syndrome: a pooled analysis from PURSUIT, PARAGON-A, PARAGON-B, and SYNERGY. Am Heart J. 2010 Dec; 160(6):1056-64, 1064.e2.

View in: PubMed

Score: 0.004

Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: A Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis. Circulation. 2010 Nov 23; 122(21):2131-41.

View in: PubMed

Score: 0.004

Impact of recovery of renal function on long-term mortality after coronary artery bypass grafting. Am J Cardiol. 2010 Dec 15; 106(12):1728-34.

View in: PubMed

Score: 0.004

Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: results from the Platelet Inhibition and Patient Outcomes (PLATO) trial. Circulation. 2010 Sep 14; 122(11):1056-67.

View in: PubMed

Score: 0.003

Effect of apixaban, an oral and direct factor Xa inhibitor, on coagulation activity biomarkers following acute coronary syndrome. Thromb Haemost. 2010 Nov; 104(5):976-83.

View in: PubMed

Score: 0.003

First clinical application of an actively reversible direct factor IXa inhibitor as an anticoagulation strategy in patients undergoing percutaneous coronary intervention. Circulation. 2010 Aug 10; 122(6):614-22.

View in: PubMed

Score: 0.003

Rationale and design of the randomized, double-blind trial testing INtraveNous and Oral administration of elinogrel, a selective and reversible P2Y(12)-receptor inhibitor, versus clopidogrel to eVAluate Tolerability and Efficacy in nonurgent Percutaneous Coronary Interventions patients (INNOVATE-PCI). Am Heart J. 2010 Jul; 160(1):65-72.

View in: PubMed

Score: 0.003

Randomized evaluation of efficacy and safety of ferric carboxymaltose in patients with iron deficiency anaemia and impaired renal function (REPAIR-IDA): rationale and study design. Nephrol Dial Transplant. 2010 Jul; 25(7):2368-75.

View in: PubMed

Score: 0.003

Towards a new order in cardiovascular medicine: re-engineering through global collaboration. Eur Heart J. 2010 Apr; 31(8):911-7.

View in: PubMed

Score: 0.003

Warfarin use and outcomes in patients with atrial fibrillation complicating acute coronary syndromes. Am J Med. 2010 Feb; 123(2):134-40.

View in: PubMed

Score: 0.003

Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study. Lancet. 2010 Jan 23; 375(9711):283-93.

View in: PubMed

Score: 0.003

Intravenous platelet blockade with cangrelor during PCI. N Engl J Med. 2009 Dec 10; 361(24):2330-41.

View in: PubMed

Score: 0.003

Standardized reporting of bleeding complications for clinical investigations in acute coronary syndromes: a proposal from the academic bleeding consensus (ABC) multidisciplinary working group. Am Heart J. 2009 Dec; 158(6):881-886.e1.

View in: PubMed

Score: 0.003

Safety and feasibility of adjunctive antiplatelet therapy with intravenous elinogrel, a direct-acting and reversible P2Y12 ADP-receptor antagonist, before primary percutaneous intervention in patients with ST-elevation myocardial infarction: the Early Rapid ReversAl of platelet thromboSis with intravenous Elinogrel before PCI to optimize reperfusion in acute Myocardial Infarction (ERASE MI) pilot trial. Am Heart J. 2009 Dec; 158(6):998-1004.e1.

View in: PubMed

Score: 0.003

Patterns of management of atrial fibrillation complicating coronary artery bypass grafting: Results from the PRoject of Ex-vivo Vein graft ENgineering via Transfection IV (PREVENT-IV) Trial. Am Heart J. 2009 Nov; 158(5):792-8.

View in: PubMed

Score: 0.003

Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention 1-year results from the STEEPLE (SafeTy and efficacy of enoxaparin in percutaneous coronary intervention patients, an international randomized evaluation) trial. JACC Cardiovasc Interv. 2009 Nov; 2(11):1083-91.

View in: PubMed

Score: 0.003

Comparison of site-reported and core laboratory-reported creatine kinase-MB values in non-ST-segment elevation acute coronary syndrome (from the international trial SYNERGY). Am J Cardiol. 2009 Nov 15; 104(10):1330-5.

View in: PubMed

Score: 0.003

Antithrombotics in acute coronary syndromes. J Am Coll Cardiol. 2009 Sep 08; 54(11):969-84.

View in: PubMed

Score: 0.003

Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009 Sep 10; 361(11):1045-57.

View in: PubMed

Score: 0.003

Sex differences in mortality following acute coronary syndromes. JAMA. 2009 Aug 26; 302(8):874-82.

View in: PubMed

Score: 0.003

Premature release of data from clinical trials of ezetimibe. N Engl J Med. 2009 Aug 13; 361(7):712-7.

View in: PubMed

Score: 0.003

Endoscopic versus open vein-graft harvesting in coronary-artery bypass surgery. N Engl J Med. 2009 Jul 16; 361(3):235-44.

View in: PubMed

Score: 0.003

Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial. Circulation. 2009 Jun 09; 119(22):2877-85.

View in: PubMed

Score: 0.003

Relationship between renal function and outcomes in high-risk patients with non-ST-segment elevation acute coronary syndromes: results from SYNERGY. Int J Cardiol. 2010 Sep 24; 144(1):36-41.

View in: PubMed

Score: 0.003

Incidence and prognostic significance of thrombocytopenia developed during acute coronary syndrome in contemporary clinical practice. Circulation. 2009 May 12; 119(18):2454-62.

View in: PubMed

Score: 0.003

Incidence, distribution, and prognostic impact of occluded culprit arteries among patients with non-ST-elevation acute coronary syndromes undergoing diagnostic angiography. Am Heart J. 2009 Apr; 157(4):716-23.

View in: PubMed

Score: 0.003

Prior polyvascular disease: risk factor for adverse ischaemic outcomes in acute coronary syndromes. Eur Heart J. 2009 May; 30(10):1195-202.

View in: PubMed

Score: 0.003

Early versus delayed, provisional eptifibatide in acute coronary syndromes. N Engl J Med. 2009 May 21; 360(21):2176-90.

View in: PubMed

Score: 0.003

ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: developed in collaboration with the American College of Chest Physicians, American Thoracic Society, Inc., and the Pulmonary Hypertension Association. Circulation. 2009 Apr 28; 119(16):2250-94.

View in: PubMed

Score: 0.003

Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomised, double-blind, placebo-controlled phase II study. Lancet. 2009 Mar 14; 373(9667):919-28.

View in: PubMed

Score: 0.003

Ethical and scientific implications of the globalization of clinical research. N Engl J Med. 2009 Feb 19; 360(8):816-23.

View in: PubMed

Score: 0.003

Optimizing trial design: sequential, adaptive, and enrichment strategies. Circulation. 2009 Feb 03; 119(4):597-605.

View in: PubMed

Score: 0.003

Aldehyde dehydrogenase activity allows reliable EPC enumeration in stored peripheral blood samples. J Thromb Thrombolysis. 2009 Oct; 28(3):259-65.

View in: PubMed

Score: 0.003

Relation between aspirin dose, all-cause mortality, and bleeding in patients with recent cerebrovascular or coronary ischemic events (from the BRAVO Trial). Am J Cardiol. 2008 Nov 15; 102(10):1285-90.

View in: PubMed

Score: 0.003

Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes. Am Heart J. 2008 Nov; 156(5):826-32.

View in: PubMed

Score: 0.003

Relation between previous lipid-lowering therapy and infarct size (creatine kinase-MB level) in patients presenting with acute myocardial infarction. Am J Cardiol. 2008 Nov 01; 102(9):1119-24.

View in: PubMed

Score: 0.003

Influence of preoperative renal dysfunction on one-year bypass graft patency and two-year outcomes in patients undergoing coronary artery bypass surgery. J Thorac Cardiovasc Surg. 2008 Nov; 136(5):1149-55.

View in: PubMed

Score: 0.003

Long-term clinical outcomes following coronary stenting. Arch Intern Med. 2008 Aug 11; 168(15):1647-55.

View in: PubMed

Score: 0.003

Impact of perioperative myocardial infarction on angiographic and clinical outcomes following coronary artery bypass grafting (from PRoject of Ex-vivo Vein graft ENgineering via Transfection [PREVENT] IV). Am J Cardiol. 2008 Sep 01; 102(5):546-51.

View in: PubMed

Score: 0.003

Phase 1b randomized study of antidote-controlled modulation of factor IXa activity in patients with stable coronary artery disease. Circulation. 2008 Jun 03; 117(22):2865-74.

View in: PubMed

Score: 0.003

Smoking status and antithrombin therapy in patients with non-ST-segment elevation acute coronary syndrome. Am Heart J. 2008 Jul; 156(1):177-84.

View in: PubMed

Score: 0.003

Efficacy and safety of pyridoxal 5'-phosphate (MC-1) in high-risk patients undergoing coronary artery bypass graft surgery: the MEND-CABG II randomized clinical trial. JAMA. 2008 Apr 16; 299(15):1777-87.

View in: PubMed

Score: 0.003

Outcomes of second revascularization procedures after stent implantation. J Med Syst. 2008 Apr; 32(2):177-86.

View in: PubMed

Score: 0.003

Cockcroft-Gault versus modification of diet in renal disease: importance of glomerular filtration rate formula for classification of chronic kidney disease in patients with non-ST-segment elevation acute coronary syndromes. J Am Coll Cardiol. 2008 Mar 11; 51(10):991-6.

View in: PubMed

Score: 0.003

Transfusion practice and outcomes in non-ST-segment elevation acute coronary syndromes. Am Heart J. 2008 Jun; 155(6):1047-53.

View in: PubMed

Score: 0.003

Noninvasive, medical management for non-ST-elevation acute coronary syndromes. Am Heart J. 2008 Mar; 155(3):397-407.

View in: PubMed

Score: 0.003

Prognostic value of troponins in patients with non-ST-segment elevation acute coronary syndromes and chronic kidney disease. Clin Cardiol. 2008 Mar; 31(3):125-9.

View in: PubMed

Score: 0.003

A randomized, double-blind, placebo-controlled, multicenter study to evaluate the cardioprotective effects of MC-1 in patients undergoing high-risk coronary artery bypass graft surgery: MC-1 to Eliminate Necrosis and Damage in Coronary Artery Bypass Graft Surgery Trial (MEND-CABG) II--study design and rationale. Am Heart J. 2008 Apr; 155(4):600-8.

View in: PubMed

Score: 0.003

Coronary artery bypass graft failure after on-pump and off-pump coronary artery bypass: findings from PREVENT IV. Ann Thorac Surg. 2008 Feb; 85(2):494-9; discussion 499-500.

View in: PubMed

Score: 0.003

Impact of saphenous vein graft radiographic markers on clinical events and angiographic parameters. Ann Thorac Surg. 2008 Feb; 85(2):520-4.

View in: PubMed

Score: 0.003

Association between bleeding, blood transfusion, and costs among patients with non-ST-segment elevation acute coronary syndromes. Am Heart J. 2008 Feb; 155(2):369-74.

View in: PubMed

Score: 0.003

Initial aspirin dose and outcome among ST-elevation myocardial infarction patients treated with fibrinolytic therapy. Circulation. 2008 Jan 15; 117(2):192-9.

View in: PubMed

Score: 0.003

Time to coronary angiography and outcomes among patients with high-risk non ST-segment elevation acute coronary syndromes: results from the SYNERGY trial. Circulation. 2007 Dec 04; 116(23):2669-77.

View in: PubMed

Score: 0.003

Clinical decisions. Management of stable coronary disease. N Engl J Med. 2007 Oct 25; 357(17):1762-6.

View in: PubMed

Score: 0.003

Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 trial. J Am Coll Cardiol. 2007 Nov 06; 50(19):1844-51.

View in: PubMed

Score: 0.003

Clinical and angiographic correlates of short- and long-term mortality in patients undergoing coronary artery bypass grafting. Am J Cardiol. 2007 Nov 15; 100(10):1538-42.

View in: PubMed

Score: 0.003

Complementary effects of thienopyridine pretreatment and platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention; results from the ESPRIT trial. Catheter Cardiovasc Interv. 2007 Jul 01; 70(1):43-50.

View in: PubMed

Score: 0.003

Effects of pyridoxal-5'-phosphate (MC-1) in patients undergoing high-risk coronary artery bypass surgery: results of the MEND-CABG randomized study. J Thorac Cardiovasc Surg. 2007 Jun; 133(6):1604-11.

View in: PubMed

Score: 0.003

Effect of nitric oxide synthase inhibition on haemodynamics and outcome of patients with persistent cardiogenic shock complicating acute myocardial infarction: a phase II dose-ranging study. Eur Heart J. 2007 May; 28(9):1109-16.

View in: PubMed

Score: 0.003

Bleeding and blood transfusion issues in patients with non-ST-segment elevation acute coronary syndromes. Eur Heart J. 2007 May; 28(10):1193-204.

View in: PubMed

Score: 0.003

Documented traditional cardiovascular risk factors and mortality in non-ST-segment elevation myocardial infarction. Am Heart J. 2007 Apr; 153(4):507-14.

View in: PubMed

Score: 0.003

Effect of tilarginine acetate in patients with acute myocardial infarction and cardiogenic shock: the TRIUMPH randomized controlled trial. JAMA. 2007 Apr 18; 297(15):1657-66.

View in: PubMed

Score: 0.003

Timing of glycoprotein IIb/IIIa inhibitor use and outcomes among patients with non-ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention (results from CRUSADE). Am J Cardiol. 2007 May 15; 99(10):1389-93.

View in: PubMed

Score: 0.003

ACCF/AHA/CDC conference report on emerging infectious diseases and biological terrorism threats: the clinical and public health implications for the prevention and control of cardiovascular diseases. Circulation. 2007 Mar 27; 115(12):1656-95.

View in: PubMed

Score: 0.003

Changes in patterns of coronary revascularization strategies for patients with acute coronary syndromes (from the CRUSADE Quality Improvement Initiative). Am J Cardiol. 2007 May 01; 99(9):1222-6.

View in: PubMed

Score: 0.003

Outcomes associated with the use of secondary prevention medications after coronary artery bypass graft surgery. Ann Thorac Surg. 2007 Mar; 83(3):993-1001.

View in: PubMed

Score: 0.003

Impact of initial heart rate and systolic blood pressure on relation of age and mortality among fibrinolytic-treated patients with acute ST-elevation myocardial infarction presenting with cardiogenic shock. Am J Cardiol. 2007 Mar 15; 99(6):793-6.

View in: PubMed

Score: 0.003

Bleeding complications in patients with acute coronary syndrome undergoing early invasive management can be reduced with radial access, smaller sheath sizes, and timely sheath removal. Catheter Cardiovasc Interv. 2007 Jan; 69(1):73-83.

View in: PubMed

Score: 0.003

A comparison of acute coronary syndrome care at academic and nonacademic hospitals. Am J Med. 2007 Jan; 120(1):40-6.

View in: PubMed

Score: 0.003

Curbing the cardiovascular disease epidemic: aligning industry, government, payers, and academics. Health Aff (Millwood). 2007 Jan-Feb; 26(1):62-74.

View in: PubMed

Score: 0.003

Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation. JAMA. 2007 Jan 10; 297(2):159-68.

View in: PubMed

Score: 0.003

Efficacy and safety of enoxaparin compared with unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention in the Superior Yield of the New Strategy of Enoxaparin, Revascularization and Glycoprotein IIb/IIIa Inhibitors (SYNERGY) trial. Am Heart J. 2006 Dec; 152(6):1042-50.

View in: PubMed

Score: 0.003

First-in-human experience of an antidote-controlled anticoagulant using RNA aptamer technology: a phase 1a pharmacodynamic evaluation of a drug-antidote pair for the controlled regulation of factor IXa activity. Circulation. 2006 Dec 05; 114(23):2490-7.

View in: PubMed

Score: 0.003

Recent trends in the care of patients with non-ST-segment elevation acute coronary syndromes: insights from the CRUSADE initiative. Arch Intern Med. 2006 Oct 09; 166(18):2027-34.

View in: PubMed

Score: 0.003

Prevalence, predictors, and outcomes of patients with non-ST-segment elevation myocardial infarction and insignificant coronary artery disease: results from the Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA Guidelines (CRUSADE) initiative. Am Heart J. 2006 Oct; 152(4):641-7.

View in: PubMed

Score: 0.003

Clinical correlates of long-term mortality after percutaneous interventions of saphenous vein grafts. Am Heart J. 2006 Oct; 152(4):801-6.

View in: PubMed

Score: 0.003

The influence of peripheral arterial disease on outcomes: a pooled analysis of mortality in eight large randomized percutaneous coronary intervention trials. J Am Coll Cardiol. 2006 Oct 17; 48(8):1567-72.

View in: PubMed

Score: 0.003

Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention. N Engl J Med. 2006 Sep 07; 355(10):1006-17.

View in: PubMed

Score: 0.003

Temporal trends in the use of early cardiac catheterization in patients with non-ST-segment elevation acute coronary syndromes (results from CRUSADE). Am J Cardiol. 2006 Nov 01; 98(9):1172-6.

View in: PubMed

Score: 0.003

Challenges in predicting the need for coronary artery bypass grafting at presentation in patients with non-ST-segment elevation acute coronary syndromes. Am J Cardiol. 2006 Sep 01; 98(5):624-7.

View in: PubMed

Score: 0.003

Impact of internal mammary artery conduit on long-term outcomes after percutaneous intervention of saphenous vein graft. Circulation. 2006 Jul 04; 114(1 Suppl):I396-401.

View in: PubMed

Score: 0.003

Provisional glycoprotein IIb/IIIa blockade in a randomized investigation of bivalirudin versus heparin plus planned glycoprotein IIb/IIIa inhibition during percutaneous coronary intervention: predictors and outcome in the Randomized Evaluation in Percutaneous coronary intervention Linking Angiomax to Reduced Clinical Events (REPLACE)-2 trial. Am Heart J. 2006 Jul; 152(1):157-63.

View in: PubMed

Score: 0.003

Low-molecular-weight heparin compared with unfractionated heparin for patients with non-ST-segment elevation acute coronary syndromes treated with glycoprotein IIb/IIIa inhibitors: results from the CRUSADE initiative. J Thromb Thrombolysis. 2006 Jun; 21(3):211-20.

View in: PubMed

Score: 0.003

The influence of risk status on guideline adherence for patients with non-ST-segment elevation acute coronary syndromes. Am Heart J. 2006 Jun; 151(6):1205-13.

View in: PubMed

Score: 0.003

Statin use and sex-specific stroke outcomes in patients with vascular disease. Stroke. 2006 Jun; 37(6):1427-31.

View in: PubMed

Score: 0.003

Association between hospital process performance and outcomes among patients with acute coronary syndromes. JAMA. 2006 Apr 26; 295(16):1912-20.

View in: PubMed

Score: 0.003

Initial experience with an intravenous P2Y12 platelet receptor antagonist in patients undergoing percutaneous coronary intervention: results from a 2-part, phase II, multicenter, randomized, placebo- and active-controlled trial. Am Heart J. 2006 Mar; 151(3):689.e1-689.e10.

View in: PubMed

Score: 0.003

Frequency and clinical implications of discordant creatine kinase-MB and troponin measurements in acute coronary syndromes. J Am Coll Cardiol. 2006 Jan 17; 47(2):312-8.

View in: PubMed

Score: 0.003

Outcomes of patients in clinical trials with ST-segment elevation myocardial infarction among countries with different gross national incomes. Eur Heart J. 2006 Mar; 27(5):527-33.

View in: PubMed

Score: 0.003

Effect of the novel direct factor Xa inhibitor DX-9065a on thrombin generation and inhibition among patients with stable atherosclerotic coronary artery disease. Thromb Res. 2006; 117(4):439-46.

View in: PubMed

Score: 0.003

Elevated creatine kinase-MB with normal creatine kinase predicts worse outcomes in patients with acute coronary syndromes: results from 4 large clinical trials. Am Heart J. 2006 Jan; 151(1):16-24.

View in: PubMed

Score: 0.003

Efficacy and safety of edifoligide, an E2F transcription factor decoy, for prevention of vein graft failure following coronary artery bypass graft surgery: PREVENT IV: a randomized controlled trial. JAMA. 2005 Nov 16; 294(19):2446-54.

View in: PubMed

Score: 0.002

Letter regarding article by Patti et al, "Randomized trial of high loading dose of clopidogrel for reduction of periprocedural myocardial infarction in patients undergoing coronary intervention: results from the ARMYDA-2 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) study". Circulation. 2005 Oct 25; 112(17):e282; author reply e283.

View in: PubMed

Score: 0.002

The PRoject of Ex-vivo Vein graft ENgineering via Transfection IV (PREVENT IV) trial: study rationale, design, and baseline patient characteristics. Am Heart J. 2005 Oct; 150(4):643-9.

View in: PubMed

Score: 0.002

Frequency, predictors, and outcomes of drug-eluting stent utilization in patients with high-risk non-ST-segment elevation acute coronary syndromes. Am J Cardiol. 2005 Sep 15; 96(6):750-5.

View in: PubMed

Score: 0.002

Relation of early saphenous vein graft failure to outcomes following coronary artery bypass surgery. Am J Cardiol. 2005 Nov 01; 96(9):1254-9.

View in: PubMed

Score: 0.002

Renal function, concomitant medication use and outcomes following acute coronary syndromes. Nephrol Dial Transplant. 2005 Oct; 20(10):2105-12.

View in: PubMed

Score: 0.002

The early glycoprotein IIb/IIIa inhibition in non-ST-segment elevation acute coronary syndrome (EARLY ACS) trial: a randomized placebo-controlled trial evaluating the clinical benefits of early front-loaded eptifibatide in the treatment of patients with non-ST-segment elevation acute coronary syndrome--study design and rationale. Am Heart J. 2005 Jun; 149(6):994-1002.

View in: PubMed

Score: 0.002

Early glycoprotein IIb/IIIa inhibitor use for non-ST-segment elevation acute coronary syndrome: patient selection and associated treatment patterns. Acad Emerg Med. 2005 May; 12(5):431-8.

View in: PubMed

Score: 0.002

Comparison of ST-segment resolution with combined fibrinolytic and glycoprotein IIb/IIIa inhibitor therapy versus fibrinolytic alone (data from four clinical trials). Am J Cardiol. 2005 Mar 01; 95(5):611-4.

View in: PubMed

Score: 0.002

Influence of clinical trial enrollment on the quality of care and outcomes for patients with non-ST-segment elevation acute coronary syndromes. Am Heart J. 2005 Mar; 149(3):474-81.

View in: PubMed

Score: 0.002

Angiographic and clinical outcomes associated with direct versus conventional stenting among patients treated with fibrinolytic therapy for ST-elevation acute myocardial infarction. Am J Cardiol. 2005 Feb 01; 95(3):383-6.

View in: PubMed

Score: 0.002

Association of smoking with improved myocardial perfusion and the angiographic characterization of myocardial tissue perfusion after fibrinolytic therapy for ST-segment elevation myocardial infarction. J Am Coll Cardiol. 2005 Jan 18; 45(2):321-3.

View in: PubMed

Score: 0.002

Incremental prognostic power of single-photon emission computed tomographic myocardial perfusion imaging in patients with known or suspected coronary artery disease. Am J Cardiol. 2005 Jan 15; 95(2):182-8.

View in: PubMed

Score: 0.002

The potential of aptamers as anticoagulants. Trends Cardiovasc Med. 2005 Jan; 15(1):41-5.

View in: PubMed

Score: 0.002

Utilization of early invasive management strategies for high-risk patients with non-ST-segment elevation acute coronary syndromes: results from the CRUSADE Quality Improvement Initiative. JAMA. 2004 Nov 03; 292(17):2096-104.

View in: PubMed

Score: 0.002

Care of non-ST-segment elevation patients: insights from the CRUSADE national quality improvement initiative. Am Heart J. 2004 Nov; 148(5 Suppl):S34-9.

View in: PubMed

Score: 0.002

Relationship of blood transfusion and clinical outcomes in patients with acute coronary syndromes. JAMA. 2004 Oct 06; 292(13):1555-62.

View in: PubMed

Score: 0.002

Thrombolysis and adjunctive therapy in acute myocardial infarction: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004 Sep; 126(3 Suppl):549S-575S.

View in: PubMed

Score: 0.002

Antithrombotic therapy during percutaneous coronary intervention: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004 Sep; 126(3 Suppl):576S-599S.

View in: PubMed

Score: 0.002

Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial. Lancet. 2004 Aug 21-27; 364(9435):675-84.

View in: PubMed

Score: 0.002

Association between platelet receptor occupancy after eptifibatide (integrilin) therapy and patency, myocardial perfusion, and ST-segment resolution among patients with ST-segment-elevation myocardial infarction: an INTEGRITI (Integrilin and Tenecteplase in Acute Myocardial Infarction) substudy. Circulation. 2004 Aug 10; 110(6):679-84.

View in: PubMed

Score: 0.002

Efficacy and bleeding complications among patients randomized to enoxaparin or unfractionated heparin for antithrombin therapy in non-ST-Segment elevation acute coronary syndromes: a systematic overview. JAMA. 2004 Jul 07; 292(1):89-96.

View in: PubMed

Score: 0.002

Rationale and strategies for implementing community-based transfer protocols for primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction. J Am Coll Cardiol. 2004 Jun 16; 43(12):2153-9.

View in: PubMed

Score: 0.002

Combined assessment of thrombolysis in myocardial infarction flow grade, myocardial perfusion grade, and ST-segment resolution to evaluate epicardial and myocardial reperfusion. Am J Cardiol. 2004 Jun 01; 93(11):1362-7, A5-6.

View in: PubMed

Score: 0.002

Six-month outcomes of percutaneous coronary balloon angioplasty in acute coronary syndromes: Results from the PURSUIT trial. Can J Cardiol. 2004 Jun; 20(8):773-8.

View in: PubMed

Score: 0.002

Association of the timing of ST-segment resolution with TIMI myocardial perfusion grade in acute myocardial infarction. Am Heart J. 2004 May; 147(5):847-52.

View in: PubMed

Score: 0.002

Association of a pulsatile blood flow pattern on coronary arteriography and short-term clinical outcomes in acute myocardial infarction. J Am Coll Cardiol. 2004 Apr 07; 43(7):1170-6.

View in: PubMed

Score: 0.002

Aspirin dose and six-month outcome after an acute coronary syndrome. J Am Coll Cardiol. 2004 Mar 17; 43(6):972-8.

View in: PubMed

Score: 0.002

Feasibility of endovascular cooling as an adjunct to primary percutaneous coronary intervention (results of the LOWTEMP pilot study). Am J Cardiol. 2004 Mar 01; 93(5):636-9.

View in: PubMed

Score: 0.002

Economic impact of drug-eluting stents on hospital systems: a disease-state model. Am Heart J. 2004 Mar; 147(3):449-56.

View in: PubMed

Score: 0.002

Improved speed and stability of ST-segment recovery with reduced-dose tenecteplase and eptifibatide compared with full-dose tenecteplase for acute ST-segment elevation myocardial infarction. J Am Coll Cardiol. 2004 Feb 18; 43(4):549-56.

View in: PubMed

Score: 0.002

Evaluating the benefits of glycoprotein IIb/IIIa inhibitors in heart failure at baseline in acute coronary syndromes. Am Heart J. 2004 Jan; 147(1):84-90.

View in: PubMed

Score: 0.002

Prognostic importance of new small Q waves following non-ST-elevation acute coronary syndromes. Am J Med. 2003 Dec 01; 115(8):613-9.

View in: PubMed

Score: 0.002

The anticoagulant therapy with bivalirudin to assist in the performance of percutaneous coronary intervention in patients with heparin-induced thrombocytopenia (ATBAT) study: main results. J Invasive Cardiol. 2003 Nov; 15(11):611-6.

View in: PubMed

Score: 0.002

Changing the model of care for patients with acute coronary syndromes. Am Heart J. 2003 Oct; 146(4):605-12.

View in: PubMed

Score: 0.002

Combining enoxaparin and glycoprotein IIb/IIIa antagonists for the treatment of acute coronary syndromes: final results of the National Investigators Collaborating on Enoxaparin-3 (NICE-3) study. Am Heart J. 2003 Oct; 146(4):628-34.

View in: PubMed

Score: 0.002

Meta-analysis of survival with platelet glycoprotein IIb/IIIa antagonists for percutaneous coronary interventions. Am J Cardiol. 2003 Sep 15; 92(6):651-5.

View in: PubMed

Score: 0.002

Reduction of myocardial ischemic injury following coronary intervention (the MC-1 to Eliminate Necrosis and Damage trial). Am J Cardiol. 2003 Sep 15; 92(6):660-4.

View in: PubMed

Score: 0.002

Frequency of stent thrombosis after acute coronary syndromes (from the SYMPHONY and 2nd SYMPHONY trials). Am J Cardiol. 2003 Aug 01; 92(3):330-3.

View in: PubMed

Score: 0.002

Randomized, double-blind, placebo-controlled, international trial of the oral IIb/IIIa antagonist lotrafiban in coronary and cerebrovascular disease. Circulation. 2003 Jul 29; 108(4):399-406.

View in: PubMed

Score: 0.002

Effect of revascularization on mortality associated with an elevated white blood cell count in acute coronary syndromes. Am J Cardiol. 2003 Jul 15; 92(2):136-40.

View in: PubMed

Score: 0.002

Poverty, process of care, and outcome in acute coronary syndromes. J Am Coll Cardiol. 2003 Jun 04; 41(11):1948-54.

View in: PubMed

Score: 0.002

Distance from the coronary ostium to the culprit lesion in acute ST-elevation myocardial infarction and its implications regarding the potential prevention of proximal plaque rupture. J Thromb Thrombolysis. 2003 Jun; 15(3):189-96.

View in: PubMed

Score: 0.002

Combination reperfusion therapy with eptifibatide and reduced-dose tenecteplase for ST-elevation myocardial infarction: results of the integrilin and tenecteplase in acute myocardial infarction (INTEGRITI) Phase II Angiographic Trial. J Am Coll Cardiol. 2003 Apr 16; 41(8):1251-60.

View in: PubMed

Score: 0.002

Troponin T and quantitative ST-segment depression offer complementary prognostic information in the risk stratification of acute coronary syndrome patients. J Am Coll Cardiol. 2003 Feb 05; 41(3):371-80.

View in: PubMed

Score: 0.002

Relationship between heparin anticoagulation and clinical outcomes in coronary stent intervention: observations from the ESPRIT trial. J Am Coll Cardiol. 2003 Feb 05; 41(3):386-93.

View in: PubMed

Score: 0.002

Frequency, patient characteristics, and outcomes of mild-to-moderate heart failure complicating ST-segment elevation acute myocardial infarction: lessons from 4 international fibrinolytic therapy trials. Am Heart J. 2003 Jan; 145(1):73-9.

View in: PubMed

Score: 0.002

Promise of combined low-molecular-weight heparin and platelet glycoprotein IIb/IIIa inhibition: results from Platelet IIb/IIIa Antagonist for the Reduction of Acute coronary syndrome events in a Global Organization Network B (PARAGON B). Am Heart J. 2002 Dec; 144(6):995-1002.

View in: PubMed

Score: 0.002

An automated strategy for bedside aPTT determination and unfractionated heparin infusion adjustment in acute coronary syndromes: insights from PARAGON A. J Thromb Thrombolysis. 2002 Aug; 14(1):33-42.

View in: PubMed

Score: 0.002

Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes. Lancet. 2002 Jul 27; 360(9329):342-3.

View in: PubMed

Score: 0.002

Early angioplasty in acute coronary syndromes without persistent ST-segment elevation improves outcome but increases the need for six-month repeat revascularization: an analysis of the PURSUIT Trial. Platelet glycoprotein IIB/IIIA in Unstable angina: Receptor Suppression Using Integrilin Therapy. J Am Coll Cardiol. 2002 Jun 19; 39(12):1924-9.

View in: PubMed

Score: 0.002

The failure of orally administered glycoprotein IIb/IIIa inhibitors to prevent recurrent cardiac events. Am J Med. 2002 Jun 01; 112(8):647-58.

View in: PubMed

Score: 0.002

Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials. Lancet. 2002 Jan 19; 359(9302):189-98.

View in: PubMed

Score: 0.002

The bent stent. J Invasive Cardiol. 2002 Jan; 14(1):54-6.

View in: PubMed

Score: 0.002

Characteristics, treatment and outcome of patients with non-ST-elevation acute coronary syndromes and multivessel coronary artery disease: observations from PURSUIT (platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrelin therapy). Cardiology. 2002; 98(4):195-201.

View in: PubMed

Score: 0.002